Add-on therapy with a single oral antihyperglycemic agent is often insufficient to provide glycemic control in patients with type 2 diabetes (T2D) uncontrolled on metformin (MET) monotherapy. This randomized, parallel-group, double-blind, 52-week trial (NCT02419612) evaluated the efficacy and safety of dual add-on therapy with dapagliflozin (DAPA) 10 mg/d + saxagliptin (SAXA) 5 mg/d vs. single add-on of titrated glimepiride (GLIM) 1-6 mg/d in patients with T2D (A1C, 7.5-10.5%) receiving stable MET ≥1500 mg/d. The primary end point was change in A1C from baseline to week 52; secondary end points were changes in body weight and systolic blood pressure (SBP) and the proportions of patients achieving A1C <7% or requiring treatment intensification by week 52. Mean±SD baseline data (N=443) were similar in both arms: age, 56.1±9.7 years; A1C, 8.5±0.8%; weight, 89.7±18.5 kg; duration of T2D, 7.8±6.4 years. DAPA + SAXA + MET resulted in significant reductions in A1C, body weight and SBP, a greater proportion of patients achieving A1C <7% and a lower proportion of patients requiring treatment intensification vs. GLIM + MET (Table). All treatments were well tolerated. Hypoglycemia incidence was lower for DAPA + SAXA + MET (18.5%) than GLIM + MET (44.0%). Add-on of DAPA + SAXA provided greater improvement in glycemic control and reduced body weight vs. GLIM in patients with T2D poorly controlled by MET.


J.P. Frias: Research Support; Self; AbbVie Inc., Allergan, Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company. Consultant; Self; CeQur Corporation. Research Support; Self; Cirius Therapeutics, AstraZeneca, Calibra Medical, Elcelyx Therapeutics, Inc.. Consultant; Self; Elcelyx Therapeutics, Inc.. Research Support; Self; Eli Lilly and Company, Genentech, Inc., Ionis Pharmaceuticals, Inc., ICON plc., Janssen Pharmaceuticals, Inc.. Consultant; Self; Johnson & Johnson Diabetes Institute, LLC.. Research Support; Self; Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc.. Consultant; Self; Ligand Pharmaceuticals, Inc.. Research Support; Self; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Pfizer Inc., Sanofi. Consultant; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Theracos, Inc.. G. Gonzalez-Galvez: None. E.K. Johnsson: Employee; Self; AstraZeneca. J. Maaske: Employee; Self; AstraZeneca. Employee; Spouse/Partner; AstraZeneca. Stock/Shareholder; Spouse/Partner; AstraZeneca. A. Peters: Advisory Panel; Self; Abbott, Bigfoot Biomedical. Research Support; Self; Dexcom, Inc.. Advisory Panel; Self; Eli Lilly and Company, Insulin Algorithms, JDRF, Lexicon Pharmaceuticals, Inc., Livongo Health. Research Support; Self; MannKind Corporation. Other Relationship; Self; Medscape. Advisory Panel; Self; Merck & Co., Inc.. Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases. Speaker's Bureau; Self; Novo Nordisk Inc.. Advisory Panel; Self; Novo Nordisk Inc., Omada Health, Inc., Optum Rx, Inc., Sanofi. Research Support; Self; T1D Exchange. Advisory Panel; Self; The Endocrine Society. Research Support; Self; The Leona M. and Harry B. Helmsley Charitable Trust. Advisory Panel; Spouse/Partner; Johnson & Johnson Diabetes Institute, LLC..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at